The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.
 
Jakub Svoboda
Research Funding - Celgene; MedImmune; Seagen
 
Lauren Strelec
Research Funding - Celgene (Inst); MedImmune (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - MedImmune
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Exelixis; Geron; Oncosec
 
Elise A Chong
No Relationships to Disclose
 
Kathleen Montrey
No Relationships to Disclose
 
Kristy Walsh
No Relationships to Disclose
 
Scott F. Huntington
Stock and Other Ownership Interests - Exelixis (I); Geron (I); Oncosec
 
Anthony Mato
Consulting or Advisory Role - Celgene; Gilead Sciences; Pharmacyclics
Speakers' Bureau - Celgene; Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Abbvie (Inst); Celgene (Inst); Emergent BioSolutions (Inst); Gilead Sciences (Inst); Pharmacyclics (Inst)
 
Daniel Jeffrey Landsburg
No Relationships to Disclose
 
Sunita Nasta
Research Funding - Millennium
 
Stephen J. Schuster
Consulting or Advisory Role - Celgene; Pharmacyclics
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Johnson & Johnson (Inst); Novartis (Inst); Pharmacyclics (Inst)